Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Respirable antisense oligonucleotides: a new drug class for respiratory disease
Autore:
Tanaka, M; Nyce, JW;
Indirizzi:
EpiGenesis Pharmaceut, Princeton, NJ 08540 USA EpiGenesis Pharmaceut Princeton NJ USA 08540 eut, Princeton, NJ 08540 USA Taisho Pharmaceut Co Ltd, Tokyo, Japan Taisho Pharmaceut Co Ltd Tokyo Japan ho Pharmaceut Co Ltd, Tokyo, Japan
Titolo Testata:
RESPIRATORY RESEARCH
fascicolo: 1, volume: 2, anno: 2001,
pagine: 5 - 9
SICI:
1465-993X(2001)2:1<5:RAOAND>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
ADENOSINE-INDUCED BRONCHOCONSTRICTION; AIRWAY-OBSTRUCTION; ASTHMA; RECEPTOR; DELIVERY;
Keywords:
asthma; DNA medicines; respiratory disease;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
17
Recensione:
Indirizzi per estratti:
Indirizzo: Nyce, JW EpiGenesis Pharmaceut, Princeton, NJ 08540 USA EpiGenesis Pharmaceut Princeton NJ USA 08540 ceton, NJ 08540 USA
Citazione:
M. Tanaka e J.W. Nyce, "Respirable antisense oligonucleotides: a new drug class for respiratory disease", RESPIR RES, 2(1), 2001, pp. 5-9

Abstract

Respirable antisense oligonucleotides (RASONs), which attenuate specific disease-associated mRNAs, represent a new class of respiratory therapeutics with considerable potential. RASONs overcome previous obstacles that have impeded the development of antisense therapeutics targeting diseases in other organ systems. RASONs are delivered directly to the target tissue via inhalation; their uptake seems to be enhanced by cationic properties inherent in pulmonary surfactant, and, because of the markedly different target properties of mRNA and proteins, they can have very long durations of effect compared with traditional drugs targeting the protein of the same gene. RASONs contain chemical modifications that decrease their degradation by cellular nucleases. However, total insensitivity to nucleases is probably not an optimal design criterion for RASONs, because moderate nuclease sensitivity can prevent their systemic delivery, decreasing the potential for systemic toxicity. EPI-2010 is a 21-mer phosphorothioate RASON that attenuates bronchoconstriction, inflammation and surfactant depletion in preclinical models of human asthma, has a duration of effect of seven days, and seems to undergo minimal systemic delivery.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 02:14:56